291 related articles for article (PubMed ID: 25483948)
41. Cardiac involvement in Fabry disease.
Linhart A; Magage S; Palecek T; Bultas J
Acta Paediatr Suppl; 2002; 91(439):15-20. PubMed ID: 12572837
[TBL] [Abstract][Full Text] [Related]
42. [Cardiomyopathy: progress in diagnosis and treatments. Topics: II. Secondary cardiomyopathy; 1. Cardiac Fabry disease].
Kubo T
Nihon Naika Gakkai Zasshi; 2014 Feb; 103(2):293-8. PubMed ID: 24724369
[No Abstract] [Full Text] [Related]
43. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.
Desnick RJ; Brady R; Barranger J; Collins AJ; Germain DP; Goldman M; Grabowski G; Packman S; Wilcox WR
Ann Intern Med; 2003 Feb; 138(4):338-46. PubMed ID: 12585833
[TBL] [Abstract][Full Text] [Related]
44. Anderson-Fabry disease: developments in diagnosis and treatment.
Mehta AB
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S66-74. PubMed ID: 20040315
[TBL] [Abstract][Full Text] [Related]
45. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
[TBL] [Abstract][Full Text] [Related]
46. Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease.
Masarone D; Duro G; Dellegrottaglie S; Colomba P; Rubino M; Cirillo A; Pisani A; Caiazza M; Elliott PM; Calabrò P; Pacileo G; Limongelli G
Future Cardiol; 2017 Nov; 13(6):521-527. PubMed ID: 28936893
[TBL] [Abstract][Full Text] [Related]
47. The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy.
Schmied C; Nowak A; Gruner C; Olinger E; Debaix H; Brauchlin A; Frank M; Reidt S; Monney P; Barbey F; Shah D; Namdar M
Heart; 2016 Aug; 102(16):1309-14. PubMed ID: 27056970
[TBL] [Abstract][Full Text] [Related]
48. Morbus Fabry of the heart. Why should cardiologists care?
Strotmann J; Weidemann F; Breunig F; Knoll A; Wanner C; Ertl G
Z Kardiol; 2005 Sep; 94(9):557-63. PubMed ID: 16142514
[TBL] [Abstract][Full Text] [Related]
49. Incidentally identified left ventricular apical aneurysm in a patient with Fabry disease.
Yim J; Gin K; Tsang TSM; Luong C; Lehman A; Ong K; Tsang MYC; Jue J; Nair P; Nasmith T; Yeung DF
Echocardiography; 2022 Aug; 39(8):1131-1137. PubMed ID: 35768900
[TBL] [Abstract][Full Text] [Related]
50. [Fabry-Anderson disease: current state of knowledge].
Vega-Vega O; Pérez-Gutiérrez A; Correa-Rotter R
Rev Invest Clin; 2011; 63(3):314-21. PubMed ID: 21888295
[TBL] [Abstract][Full Text] [Related]
51. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
52. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking.
Das AM; Naim HY
Adv Clin Chem; 2009; 49():57-71. PubMed ID: 19947355
[TBL] [Abstract][Full Text] [Related]
53. [A case of Anderson-Fabry disease: a multidisciplinary approach for diagnosis and follow up].
Zito A; De Pascalis A; Armeni A; Ria P; Barbarini L; Caggiula M; My F; Barbarini S; Trianni G; Napoli M
G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234233
[TBL] [Abstract][Full Text] [Related]
54. When should cardiologists suspect Anderson-Fabry disease?
Gambarin FI; Disabella E; Narula J; Diegoli M; Grasso M; Serio A; Favalli BM; Agozzino M; Tavazzi L; Fraser AG; Arbustini E
Am J Cardiol; 2010 Nov; 106(10):1492-9. PubMed ID: 21059442
[TBL] [Abstract][Full Text] [Related]
55. A diagnosis of Fabry gastrointestinal disease by chance: a case report.
Feriozzi S; Torre ES; Ranalli TV; Cardello P; Morrone A; Ancarani E
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):163-5. PubMed ID: 17273003
[TBL] [Abstract][Full Text] [Related]
56. Early detection of Fabry cardiomyopathy by tissue Doppler imaging.
Pieroni M; Chimenti C; Ricci R; Sale P; Russo MA; Frustaci A
Circulation; 2003 Apr; 107(15):1978-84. PubMed ID: 12668521
[TBL] [Abstract][Full Text] [Related]
57. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
58. Echocardiographic Assessment of Patients with Fabry Disease.
Yeung DF; Sirrs S; Tsang MYC; Gin K; Luong C; Jue J; Nair P; Lee PK; Tsang TSM
J Am Soc Echocardiogr; 2018 Jun; 31(6):639-649.e2. PubMed ID: 29606333
[TBL] [Abstract][Full Text] [Related]
59. A Review of Fabry Disease.
Chan B; Adam DN
Skin Therapy Lett; 2018 Mar; 23(2):4-6. PubMed ID: 29562089
[TBL] [Abstract][Full Text] [Related]
60. Cardiac involvement in Lysosomal Storage Diseases.
Sestito S; Parisi F; Tallarico V; Tarsitano F; Roppa K; Pensabene L; Chimenz R; Ceravolo G; Calabrò MP; De Sarro R; Moricca MT; Bonapace G; Concolino D
J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 2):107-119. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. PubMed ID: 33000609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
